Sweden · Delayed Price · Currency is SEK Genovis AB (publ.) Statistics
Total Valuation
STO:GENO has a market cap or net worth of SEK 1.30 billion. The enterprise value is 1.20 billion.
| Market Cap | 1.30B |
| Enterprise Value | 1.20B |
Important Dates
The next confirmed earnings date is Thursday, July 23, 2026.
| Earnings Date | Jul 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
STO:GENO has 66.06 million shares outstanding. The number of shares has increased by 0.71% in one year.
| Current Share Class | 66.06M |
| Shares Outstanding | 66.06M |
| Shares Change (YoY) | +0.71% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 16.44% |
| Owned by Institutions (%) | 36.06% |
| Float | 55.20M |
Valuation Ratios
The trailing PE ratio is 53.45 and the forward PE ratio is 42.59. STO:GENO's PEG ratio is 25.97.
| PE Ratio | 53.45 |
| Forward PE | 42.59 |
| PS Ratio | 9.93 |
| PB Ratio | 4.69 |
| P/TBV Ratio | 6.55 |
| P/FCF Ratio | 36.05 |
| P/OCF Ratio | 34.36 |
| PEG Ratio | 25.97 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.26, with an EV/FCF ratio of 33.34.
| EV / Earnings | 49.53 |
| EV / Sales | 9.18 |
| EV / EBITDA | 27.26 |
| EV / EBIT | 39.07 |
| EV / FCF | 33.34 |
Financial Position
The company has a current ratio of 7.65, with a Debt / Equity ratio of 0.26.
| Current Ratio | 7.65 |
| Quick Ratio | 6.14 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | 1.95 |
| Debt / FCF | 2.02 |
| Interest Coverage | 6.08 |
Financial Efficiency
Return on equity (ROE) is 9.53% and return on invested capital (ROIC) is 12.36%.
| Return on Equity (ROE) | 9.53% |
| Return on Assets (ROA) | 4.22% |
| Return on Invested Capital (ROIC) | 12.36% |
| Return on Capital Employed (ROCE) | 6.79% |
| Weighted Average Cost of Capital (WACC) | 13.31% |
| Revenue Per Employee | 3.64M |
| Profits Per Employee | 674,972 |
| Employee Count | 36 |
| Asset Turnover | 0.37 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, STO:GENO has paid 1.92 million in taxes.
| Income Tax | 1.92M |
| Effective Tax Rate | 7.32% |
Stock Price Statistics
The stock price has decreased by -24.52% in the last 52 weeks. The beta is 1.73, so STO:GENO's price volatility has been higher than the market average.
| Beta (5Y) | 1.73 |
| 52-Week Price Change | -24.52% |
| 50-Day Moving Average | 19.63 |
| 200-Day Moving Average | 20.65 |
| Relative Strength Index (RSI) | 48.35 |
| Average Volume (20 Days) | 49,204 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, STO:GENO had revenue of SEK 131.09 million and earned 24.30 million in profits. Earnings per share was 0.37.
| Revenue | 131.09M |
| Gross Profit | 116.81M |
| Operating Income | 24.06M |
| Pretax Income | 26.22M |
| Net Income | 24.30M |
| EBITDA | 30.62M |
| EBIT | 24.06M |
| Earnings Per Share (EPS) | 0.37 |
Balance Sheet
The company has 170.93 million in cash and 73.01 million in debt, with a net cash position of 97.93 million or 1.48 per share.
| Cash & Cash Equivalents | 170.93M |
| Total Debt | 73.01M |
| Net Cash | 97.93M |
| Net Cash Per Share | 1.48 |
| Equity (Book Value) | 277.36M |
| Book Value Per Share | 4.20 |
| Working Capital | 185.02M |
Cash Flow
In the last 12 months, operating cash flow was 37.88 million and capital expenditures -1.78 million, giving a free cash flow of 36.10 million.
| Operating Cash Flow | 37.88M |
| Capital Expenditures | -1.78M |
| Depreciation & Amortization | 6.56M |
| Net Borrowing | -572,000 |
| Free Cash Flow | 36.10M |
| FCF Per Share | 0.55 |
Margins
Gross margin is 89.10%, with operating and profit margins of 18.35% and 18.54%.
| Gross Margin | 89.10% |
| Operating Margin | 18.35% |
| Pretax Margin | 20.00% |
| Profit Margin | 18.54% |
| EBITDA Margin | 23.36% |
| EBIT Margin | 18.35% |
| FCF Margin | 27.54% |
Dividends & Yields
STO:GENO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.71% |
| Shareholder Yield | -0.71% |
| Earnings Yield | 1.87% |
| FCF Yield | 2.77% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for STO:GENO is 32.67, which is 65.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 32.67 |
| Price Target Difference | 65.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 21.29% |
| EPS Growth Forecast (3Y) | 34.71% |
Stock Splits
The last stock split was on April 4, 2012. It was a reverse split with a ratio of 0.1.
| Last Split Date | Apr 4, 2012 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |